Milton Grannatt, PhD, SymBio Pharmaceuticals
Dr. Grannatt retired September 2012 after 25 years in the global pharmaceuticals industry. He was Vice President of Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex Service, an acquisitive, diversified UK-based company. Dr. Grannatt has an extensive deal sheet.
Dr. Grannatt currently serves as an outside Director of SymBio Pharmaceuticals Limited, a publicly-traded Japanese pharmaceutical company; an outside Director of Myostin, an Australian biotech company; an outside Director of ARKAY, a US-based start up; a member of the advisory boards of VOX Telehealth and BioHealthonomics Inc; and an advisor to selected other biotech companies. In addition, he is a lecturer in economics at Princeton’s Evergreen Forum.
Dr. Grannatt received his undergraduate degree and PhD in economics from Lehigh University.